Yvonne Y Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12190731/publications.pdf

Version: 2024-02-01

361413 526287 3,049 28 20 27 h-index citations g-index papers 28 28 28 6226 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Research, 2016, 76, 999-1008.	0.9	451
2	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	27.8	374
3	Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma. Clinical Cancer Research, 2015, 21, 1447-1456.	7.0	235
4	Exome and genome sequencing of nasopharynx cancer identifies NF- $\hat{\mathbb{P}}$ B pathway activating mutations. Nature Communications, 2017, 8, 14121.	12.8	227
5	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell, 2021, 184, 6119-6137.e26.	28.9	201
6	Drug repositioning for personalized medicine. Genome Medicine, 2012, 4, 27.	8.2	186
7	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Journal of Thoracic Oncology, 2022, 17, 399-410.	1.1	151
8	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC. Clinical Cancer Research, 2020, 26, 2615-2625.	7.0	129
9	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight, 2016, 1, e87415.	5.0	125
10	Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 2022, 8, 1160.	7.1	117
11	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discovery, 2016, 6, 1006-1021.	9.4	108
12	A Computational Approach to Finding Novel Targets for Existing Drugs. PLoS Computational Biology, 2011, 7, e1002139.	3 . 2	107
13	Genomic Landscape of Human Papillomavirus–Associated Cancers. Clinical Cancer Research, 2015, 21, 2009-2019.	7.0	104
14	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 4135-4142.	7.0	95
15	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity., 2019, 7, 32.		92
16	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2939-2949.	7.0	51
17	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. Journal of Thoracic Oncology, 2021, 16, 1176-1187.	1.1	49
18	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	3.4	47

#	Article	IF	CITATION
19	Sex-Biased <i>ZRSR2 < i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discovery, 2022, 12, 522-541.</i>	9.4	44
20	NSCLC Driven by <i>DDR2</i> Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. Molecular Cancer Therapeutics, 2015, 14, 2382-2389.	4.1	29
21	Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Molecular Cancer Research, 2019, 17, 2281-2293.	3.4	29
22	Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Reports, 2020, 33, 108493.	6.4	28
23	Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 1105-1118.	7.0	24
24	Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics, 2021, 37, 2461-2463.	4.1	21
25	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clinical Cancer Research, 2021, 27, 1695-1705.	7.0	19
26	Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa155.	0.7	4
27	Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis. Blood, 2020, 136, 13-14.	1.4	1
28	Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts) Journal of Clinical Oncology, 2016, 34, 6052-6052.	1.6	1